A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Oltipraz (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Registrational; Therapeutic Use
- Sponsors PharmaKing
Most Recent Events
- 05 Oct 2022 Status changed from recruiting to completed.
- 27 Nov 2019 Status changed from not yet recruiting to recruiting.
- 04 Nov 2019 Planned initiation date changed from 1 Oct 2019 to 1 Nov 2019.